Clinical Trial: A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07814248) titled 'A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors' on Aug. 31.

Brief Summary: A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.

The main goals of this study are to:

* Find the recommended dose of TS-104 that can safely be given to participants

* Learn more about the side effects of TS-104

* Learn more about the effectiveness of TS-104

* Learn ...